Lexeo Therapeutics (LXEO) announced the appointment of Tim Van Hauwermeiren, co-founder and CEO of argenx SE (ARGX), as an independent, non-executive director to its Board of Directors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
- Lexeo Therapeutics initiated with an Outperform at Baird
- Lexeo Therapeutics initiated with a Buy at H.C. Wainwright
- Lexeo sees cash, equivalents sufficient to fund operations into 2027
- Lexeo Therapeutics reports Q1 EPS (77c), consensus (77c)